{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:19:08Z","timestamp":1783019948831,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Monoacylglycerol lipase (MAGL) is a key serine hydrolase which terminates endocannabinoid signaling and regulates arachidonic acid driven inflammatory responses within the central nervous system. To develop [\n                      <jats:sup>11<\/jats:sup>\n                      C]PF-06809247 into a clinically usable MAGL positron emission tomography (PET) radioligand, we assessed the occupancy of MAGL by an inhibitor in the non-human primate (NHP) brain. Additionally, we measured the whole-body distribution of [\n                      <jats:sup>11<\/jats:sup>\n                      C]PF-06809247 in NHP and estimated human effective radiation doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Seven cynomolgus monkeys were enrolled for brain PET measurements. Two PET measurements along with arterial blood sampling were performed in each NHP: one baseline and one pretreatment condition with intravenous administration of PF-06818883, a pro-drug of a selective MAGL inhibitor (total of seven doses between 0.01 and 1.27\u00a0mg\/kg). Kinetic parameters\n                      <jats:italic>K<\/jats:italic>\n                      <jats:sub>1<\/jats:sub>\n                      ,\n                      <jats:italic>k<\/jats:italic>\n                      <jats:sub>2<\/jats:sub>\n                      and\n                      <jats:italic>k<\/jats:italic>\n                      <jats:sub>3<\/jats:sub>\n                      were estimated by a two tissue compartment (2TC) model using metabolite corrected plasma radioactivity as the input function.\n                      <jats:italic>k<\/jats:italic>\n                      <jats:sub>4<\/jats:sub>\n                      was set as 0 according to the irreversible binding of [\n                      <jats:sup>11<\/jats:sup>\n                      C]PF-06809247.\n                      <jats:italic>K<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>i<\/jats:italic>\n                      <\/jats:sub>\n                      by 2TC and Patlak analysis were calculated as the influx constant. The target occupancy was calculated using\n                      <jats:italic>K<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>i<\/jats:italic>\n                      <\/jats:sub>\n                      at baseline and pretreatment conditions. Two cynomolgus monkeys were enrolled for whole-body PET measurements. Estimates of the absorbed radiation dose in humans were calculated with OLINDA\/EXM 1.1 using the adult male reference model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Radioactivity retention was decreased in all brain regions following pretreatment with PF-06818883. Occupancy was measured as 25.4\u2013100.5% in a dose dependent manner. Whole-body PET showed high radioactivity uptake values in the liver, small intestine, kidney, and brain. The effective dose of [\n                      <jats:sup>11<\/jats:sup>\n                      C]PF-06809247 was calculated as 4.3\u00a0\u03bcSv\/MBq.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>11<\/jats:sup>\n                      C]PF-06809247 is a promising PET ligand for further studies of MAGL in the human brain.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-022-00882-2","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:38:28Z","timestamp":1646383108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-1361","authenticated-orcid":false,"given":"Ryosuke","family":"Arakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangram","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Maresca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund J.","family":"Keliher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin R.","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Samad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deane","family":"Nason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Trapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari R.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Litchfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Halldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"882_CR1","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1021\/acschemneuro.0c00305","volume":"11","author":"C Varlow","year":"2020","unstructured":"Varlow C, Boileau I, Wey HY, Liang SH, Vasdev N. Classics in neuroimaging: imaging the endocannabinoid pathway with PET. ACS Chem Neurosci. 2020;11:1855\u201362.","journal-title":"ACS Chem Neurosci"},{"key":"882_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.drudis.2019.10.004","volume":"25","author":"NL Grimsey","year":"2020","unstructured":"Grimsey NL, Savinainen JR, Attili B, Ahamed M. Regulating membrane lipid levels at the synapse by small-molecule inhibitors of monoacylglycerol lipase: new developments in therapeutic and PET imaging applications. Drug Discov Today. 2020;25:330\u201343.","journal-title":"Drug Discov Today"},{"key":"882_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/epi.13950","volume":"59","author":"G Terrone","year":"2018","unstructured":"Terrone G, Pauletti A, Salamone A, et al. Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. Epilepsia. 2018;59:79\u201391.","journal-title":"Epilepsia"},{"key":"882_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-018-1166-9","volume":"15","author":"JR Piro","year":"2018","unstructured":"Piro JR, Suidan GL, Quan J, et al. Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury. J Neuroinflammation. 2018;15:1\u201315.","journal-title":"J Neuroinflammation"},{"key":"882_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.celrep.2012.05.001","volume":"1","author":"JR Piro","year":"2012","unstructured":"Piro JR, Benjamin DI, Duerr JM, et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer\u2019s disease. Cell Rep. 2012;1:617\u201323.","journal-title":"Cell Rep"},{"key":"882_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.biopsych.2020.01.015","volume":"88","author":"G Bedse","year":"2020","unstructured":"Bedse G, Hill MN, Patel S. 2-Arachidonoylglycerol modulation of anxiety and stress adaptation: from grass roots to novel therapeutics. Biol Psychiatry. 2020;88:520\u201330.","journal-title":"Biol Psychiatry"},{"key":"882_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bcp.2018.07.036","volume":"157","author":"A Gil-Ord\u00f3\u00f1ez","year":"2018","unstructured":"Gil-Ord\u00f3\u00f1ez A, Mart\u00edn-Fontecha M, Ortega-Guti\u00e9rrez S, L\u00f3pez-Rodr\u00edguez ML. Monoacylglycerol lipase (MAGL) as a promising therapeutic target. Biochem Pharmacol. 2018;157:18\u201332.","journal-title":"Biochem Pharmacol"},{"key":"882_CR8","doi-asserted-by":"publisher","first-page":"8532","DOI":"10.1021\/acs.jmedchem.9b00847","volume":"62","author":"L Zhang","year":"2019","unstructured":"Zhang L, Butler CR, Maresca KP, et al. Identification and development of an irreversible monoacylglycerol lipase (MAGL) positron emission tomography (PET) radioligand with high specificity. J Med Chem. 2019;62:8532\u201343.","journal-title":"J Med Chem"},{"key":"882_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00259-009-1156-3","volume":"36","author":"A Varrone","year":"2009","unstructured":"Varrone A, Sj\u00f6holm N, Eriksson L, Guly\u00e1s B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"882_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trac.2018.10.019","volume":"110","author":"MM Moein","year":"2019","unstructured":"Moein MM, Nakao R, Amini N, Abdel-Rehim M, Schou M, Halldin C. Sample preparation techniques for radiometabolite analysis of positron emission tomography radioligands; trends, progress, limitations and future prospects. TrAC Trends Anal Chem. 2019;110:1\u20137.","journal-title":"TrAC Trends Anal Chem"},{"key":"882_CR11","doi-asserted-by":"publisher","first-page":"121220","DOI":"10.1016\/j.talanta.2020.121220","volume":"219","author":"MM Moein","year":"2020","unstructured":"Moein MM, Halldin C. Sample preparation techniques for protein binding measurement in radiopharmaceutical approaches: a short review. Talanta. 2020;219:121220.","journal-title":"Talanta"},{"key":"882_CR12","unstructured":"Butler C, McAllister L, Beck E, et al. 1,1,1-Trifluoro-3-hydroxypropan-2-Yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-Yl carbamate derivatives As Magl inhibitors. Us20170029390. 2017."},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"key":"882_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jcbfm.1983.1","volume":"3","author":"CS Patlak","year":"1983","unstructured":"Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"key":"882_CR15","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"882_CR16","doi-asserted-by":"publisher","first-page":"10819","DOI":"10.1073\/pnas.152334899","volume":"99","author":"TP Dinh","year":"2002","unstructured":"Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002;99:10819\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"882_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/jcbfm.2010.55","volume":"31","author":"K Varn\u00e4s","year":"2011","unstructured":"Varn\u00e4s K, Nyberg S, Halldin C, et al. Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2011;31:113\u201323.","journal-title":"J Cereb Blood Flow Metab"},{"key":"882_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00259-011-2005-8","volume":"39","author":"P Zanotti-Fregonara","year":"2012","unstructured":"Zanotti-Fregonara P, Innis RB. Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2012;39:544\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"882_CR19","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1021\/acs.jmedchem.7b01400","volume":"61","author":"R Cheng","year":"2018","unstructured":"Cheng R, Mori W, Ma L, et al. In vitro and in vivo evaluation of 11 C-labeled azetidinecarboxylates for imaging monoacylglycerol lipase by PET imaging studies. J Med Chem. 2018;61:2278\u201391.","journal-title":"J Med Chem"},{"key":"882_CR20","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.7150\/thno.15257","volume":"6","author":"L Wang","year":"2016","unstructured":"Wang L, Mori W, Cheng R, et al. Synthesis and preclinical evaluation of sulfonamidobased [11C-Carbonyl]-carbamates and ureas for imaging monoacylglycerol lipase. Theranostics. 2016;6:1145\u201359.","journal-title":"Theranostics"},{"key":"882_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejmech.2017.04.066","volume":"136","author":"M Ahamed","year":"2017","unstructured":"Ahamed M, Attili B, van Veghel D, et al. Synthesis and preclinical evaluation of [11C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL). Eur J Med Chem. 2017;136:104\u201313.","journal-title":"Eur J Med Chem"},{"key":"882_CR22","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1021\/acs.jmedchem.8b01576","volume":"62","author":"Y Hattori","year":"2019","unstructured":"Hattori Y, Aoyama K, Maeda J, et al. Design, synthesis, and evaluation of (4 R)-1-{3-[2-(18F)fluoro-4-methylpyridin-3-yl]phenyl}-4-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]pyrrolidin-2-one ([18F] T-401) as a novel positron-emission tomography imaging agent for monoacylglycerol lipase. J Med Chem. 2019;62:2362\u201375.","journal-title":"J Med Chem"},{"key":"882_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1021\/acs.jmedchem.0c01459","volume":"64","author":"L Hou","year":"2021","unstructured":"Hou L, Rong J, Haider A, et al. Positron emission tomography imaging of the endocannabinoid system: opportunities and challenges in radiotracer development. J Med Chem. 2021;64:123\u201349.","journal-title":"J Med Chem"},{"key":"882_CR24","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1097\/00004647-199910000-00012","volume":"19","author":"RA Koeppe","year":"1999","unstructured":"Koeppe RA, Frey KA, Snyder SE, Meyer P, Kilbourn MR, Kuhl DE. Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab. 1999;19:1150\u201363.","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-022-00882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-022-00882-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-022-00882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:43:08Z","timestamp":1646383388000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-022-00882-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1186\/s13550-022-00882-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-510615\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-510615\/v1","asserted-by":"object"}]},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were approved by the Animal Ethics Committee of the Swedish Animal Welfare Agency (N185\/14) and performed according to \u201cGuidelines for planning, conducting and documenting experimental research\u201d (Dnr 4820\/06-600) of Karolinska Institutet.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kevin P. Maresca, Lei Zhang, Edmund J. Keliher, Christopher R. Butler, Justin R. Piro, Tarek A. Samad, Deborah Smith, Deane Nason, Steve O\u2019Neil, Patrick Trapa, Kari R. Fonseca, John Litchfield, and Timothy McCarthy were employees of Pfizer Inc. when the study was conducted. Other authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}